Drugs for type 2 diabetes: Role in the regulation of bone metabolism

Clinical Cases in Mineral and Bone Metabolism

Volumn 12, Issue 2, 2015, Pages 130-134

  Mannucci, Edoardo ^a   Dicembrini, Ilaria ^a  

^a Careggi Teaching Hospital   (Italy)

Author keywords

Bone fractures; Diabetes; Osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE;

BONE ATROPHY; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL (TOPIC); FRACTURE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; REVIEW; RISK ASSESSMENT;

EID: 84945540155     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: 10.11138/ccmbm/2015.12.2.130     Document Type: Review

References (34)

1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglita-zone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-2443.
2. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845-851.
3. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
4. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32:187-202.
5. Glintborg D, Andersen M, Hagen C, et al. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008;93:1696-1701.
6. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115-123.
7. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18 Suppl 2:S10-S15.
8. Fürnsinn C, Waldhäusl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia. 2002;45:1211-1223.
9. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipo-genesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 2007;30:RC26-RC30.
10. Beck GR Jr, Khazai NB, Bouloux GF, et al. The effects of thiazolidine-diones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res. 2013;161:145-155.
11. Grey A, Beckley V, Doyle A, et al. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. Eur J Endocrinol. 2012;166:1087-1091.
12. Bilezikian JP, Josse RG, Eastell R, et al.Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:1519-1528.
13. van Lierop AH, Hamdy NA, van der Meer RW, et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J En-docrinol. 2012;166:711-716.
14. Zanchi A, Pechère-Bertschi A, Burnier M, Bonny O.Effects of pioglita-zone on renal calcium excretion. J Clin Endocrinol Metab. 2011; 96:E1482-E1485.
15. Rubin MR, Manavalan JS, Agarwal S, et al. Effects of rosiglitazone vs metformin on circulating osteoclast and osteogenic precursor cells in postmenopausal women with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2014;99:E1933-E1942.
16. Klein GL. Insulin and bone: Recent developments. World J Diabetes. 2014; 5:14-16.
17. Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig. 2013;33:621-631.
18. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypo-glycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2008;31:199-203.
19. Signorovitch JE, Macaulay D, Diener M, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab. 2013;15:3353-41.
20. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.
21. Jang WG, Kim EJ, Bae IH, et al. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone. 2011;48:885-893.
22. Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000;141:1228-1235.
23. Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008;149:574-579.
24. Nuche-Berenguer B, Moreno P, Portal-Nuñez S, et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 2010;159:61-66.
25. Nuche-Berenguer B, Lozano D, Gutiérrez-Rojas I, et al. GLP-1 and ex-endin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol. 2011;209:203-210.
26. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol. 2011;11:12.
27. Nuche-Berenguer B, Portal-Núñez S, Moreno P, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 2010;225:585-592.
28. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34:2474-2476.
29. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335.
30. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
31. Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials. Endocrine. 2014 Jul 30. [Epub ahead of print]
32. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160:909-917.
33. Bunck MC, Eliasson B, Cornér A, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:374-377.
34. European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Assessment report of Forxiga (dapagliflozin), Procedure EMEA/H/C/002322. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/hu-man/002322/WC500136024.pdf